01349 FUDANZHANGJIANG
- 2.220
- +0.050+2.30%
FUDANZHANGJIANG News
Shanghai Fudan-Zhangjiang Buys Structured Deposits Worth 200 Million Yuan
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349) has bought structured deposit products worth 200 million yuan from the Shanghai Pudong Development Bank (SHA:600000) this month, according to Mo
Fudan Zhangjiang (01349.HK) subscribes to SPD Bank structured deposit products
Gelonghui, April 22丨Fudan Zhangjiang (01349.HK) announced that on April 1, 2024, the company signed SPD Bank Structured Deposit Product Agreement I with SPD Bank, agreeing to use its own idle funds generated from daily operations to subscribe SPD for structured deposit products with a total amount of RMB 100 million. On April 22, 2024, the company and SPD Bank signed SPD Bank Structured Deposit Product Agreement II, agreeing to subscribe SPD Bank for structured deposit products with a total amount of RMB 100 million using its own idle funds generated from daily operations.
Fudan Zhangjiang (01349.HK) held a board meeting on April 29th to review and approve the first quarter results
Gelonghui, April 15, 丨 Fudan Zhangjiang (01349.HK) announced that a board meeting will be held on April 29, 2024 (Monday) to review and approve (including) the unaudited results of the company and its subsidiaries for the first quarter ended March 31, 2024 and their announcements.
Fudan Zhangjiang (01349.HK) subscribes to 180 million yuan of Bank of China structured deposit products
Gelonghui, April 3, 丨 Fudan Zhangjiang (01349.HK) issued an announcement. Recently, the company signed a structured deposit product agreement with the Bank of China and agreed to use temporary idle funds raised from the public offering of A-shares to subscribe to structured deposit products with a total amount of RMB 180 million from the Bank of China.
Fudan Zhangjiang (01349.HK) subscribes to Ping An Bank structured deposit products
Gelonghui, April 2: Fudan Zhangjiang (01349.HK) issued an announcement. Recently, the company signed Ping An Bank Structured Deposit Product Agreement I with Ping An Bank, agreeing to subscribe to structured deposit products with a total amount of RMB 300 million from Ping An Bank using its own idle funds generated from daily operations; and signed Ping An Bank Structured Deposit Product Agreement II with Ping An Bank to subscribe to structured deposit products with a total amount of RMB 57 million from the public offering of A-shares.
FUDANZHANGJIANG To Go Ex-Dividend On July 4th, 2024 With 0.07719 HKD Dividend Per Share
April 2nd - $FUDANZHANGJIANG(01349.HK)$ is trading ex-dividend on July 4th, 2024. Shareholders of record on July 5th, 2024 will receive 0.07719 HKD dividend per share on August 26th, 2024. The ex-
Fudan-Zhangjiang Bio Sees Profit, Revenue Drop in 2023
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349, SHA:688505) reported profit attributable to shareholders of 108.6 million yuan for the 12 months ended Dec. 31, 2023, compared with 138 million
FUDANZHANGJIANG: Annual Results Announcement For the Year Ended 31 December 2023
Fudan Zhangjiang (01349): Deputy General Manager and Core Technician Li Xiaowen leaves office
Zhitong Finance App News, Fudan Zhangjiang (01349) issued an announcement. The board of directors recently received a written resignation report from Li Xiaowen, the company's deputy general manager and core technical staff. Li Xiaowen applied to resign from his position due to personal reasons. After his resignation, Li Xiaowen will no longer hold any position in the company. The resignation report will take effect on the day it is delivered to the company's board of directors. The work that Li Xiaowen is responsible for is being handed over. His departure will not have a significant adverse impact on the company's R&D capabilities, sustainable management capabilities and core competitiveness, nor will it affect the development of the company's existing core technology and R&D projects. The company's research and development and clinical operation management work are all
Fudan Zhangjiang (01349) plans to renew PwC Zhongtian
Fudan Zhangjiang (01349) issued an announcement. The company will hold the 5th meeting of the 8th board of directors on March 28, 2024...
Fudan Zhangjiang (688505.SH) announced 2023 annual results, net profit of 109 million yuan, down 21.28% year on year
Fudan Zhangjiang (688505.SH) disclosed its 2023 annual report. The company achieved operating income of 8 during the reporting period...
Fudan Zhangjiang (01349.HK) plans to hold a board meeting on March 28 to approve the annual results
Gelonghui, March 15, 丨 Fudan Zhangjiang (01349.HK) announced that a board meeting will be held on March 28, 2024 (Thursday) to review and approve (including) the results of the company and its subsidiaries for the year ended 31 December 2023 and consider payment of a final dividend, if any.
Fudan Zhangjiang (01349) Net profit of about 109 million yuan in 2023 decreased by 21.28% year-on-year
Fudan Zhangjiang (01349) announced its 2023 performance report. Operating revenue was about 851 million yuan, a year-on-year decrease of 17...
FUDANZHANGJIANG: INSIDE INFORMATION-ANNOUNCEMENT OF PRELIMINARY ANNUAL RESULTS FOR THE YEAR 2023
Fudan Zhangjiang (01349) fell 1.40% to 2.130 yuan, a 52-week low
As of 16:08 Fudan Zhangjiang (01349), down 1.40% from yesterday's closing price, now reports a 52-week low of $2.130; the trading volume is 606 million shares, with a turnover of HK$1,283,300.
Fudan-Zhangjiang Bio-Pharmaceutical to Subscribe for Deposit Products Worth 357 Million Yuan
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349, SHA:688505) agreed to subscribe for structured deposit products totaling 357 million yuan from Ping An Bank (SHE:000001) to utilize its idle fu
Fudan-Zhangjiang Invests 357 Million Yuan in Ping An Bank Structured Deposit Products
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349, SHA:688505) will subscribe for two structured deposit products offered by Ping An Bank worth a total of 357 million yuan. The company will use i
Fudan Zhangjiang (688505.SH) received a government subsidy of 23.23 million yuan
Fudan Zhangjiang (688505.SH) issued an announcement. The company and its subsidiary Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd.,...
Fudan-Zhangjiang Unit's Clinical Trial Application for Glioma Visualization Agent Accepted in China
China's National Medical Products Administration has accepted an application by a subsidiary of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349, SHA:688505) for the clinical trial of aminolevul
[BT Financial Report Instantaneous Analysis] Fudan Zhangjiang 2023 Three-Quarter Report: Net profit has risen sharply, R&D investment continues to innovate
Fudan Zhangjiang (stock code: 688505) is an innovative enterprise focusing on biomedicine, dedicated to developing and marketing new drugs to meet the needs of clinical treatment. The company continues to explore and break through with the purpose of “We explore more, and humans are healthier”, and strives to become an innovator and leader in the biomedical industry. Facing the challenges and opportunities of the pharmaceutical industry, Fudan Zhangjiang has made continuous efforts to contribute to the development of human health. In terms of assets and liabilities, as of the end of the third quarter of 2023, the total assets of Fudan Zhangjiang were 2,946 billion yuan, compared with 29 at the end of the previous year
Analysis
Price Target
No Data
